Researchers at PSI have developed a new drug that could increase the survival chances of patients with metastatic prostate cancer. The drug is now being tested on patients in the PROGNOSTICS project. A research consortium consisting of the Paul Scherrer Institute, the University Hospital Basel and ETH Zurich is receiving two million Swiss francs in funding for this project. Main PROGNOSTICS applicants (from left to right): Roger Schibli, Head of the Center for Radiopharmaceutical Science ETH-PSI; Damian Wild, Head of Nuclear MedicineUniversity Hospital Basel; Nicola Aceto, ETH Zurich Department Biology Roger Schibli heads the Centre for Radiopharmaceutical Science ETH-PSI.

https://www.miragenews.com/www.miragenews.com/fighting-tumours-down-to-last-cancer-cell-1039675/

#miragenews